A brief overview of biosimilars and factors limiting their uptake

Health Canada. Fact sheet: biosimilars. 2017. Available: https://www.canada.ca/content/dam/hc-sc/migration/hc-sc/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/biosimilars-biosimilaires-qa-qr-eng.pdf (accessed Oct. 11, 2018).

Canadian Institute for Health information. Prescribed drug spending in Canada, 2017: a focus on public drug programs. Ottawa (ON): CIHI; 2017. Available: https://secure.cihi.ca/free_products/pdex2017-report-en.pdf (accessed Oct. 11, 2018).

Rifkin RM Peck SR. Biosimilars: implications for clinical practice. J Oncol Pract 2017;13(9, suppl):24s-31s.

Government of Canada. Guidance document: information and submission requirements for biosimilar biologic drugs. Ottawa (ON): CADTH; 2017. Available: https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/information-submission-requirements-biosimilar-biologic-drugs-1.html#inf (accessed Oct. 15, 2018).

van Overbeeke E De Beleyr B de Hoon J , et al. Perception of originator biologics and biosimilars: a survey among Belgian rheumatoid arthritis patients and rheumatologists. BioDrugs 2017;31(5):447-59.

Lesaffre E. Superiority, equivalence and non-inferiority trials. Bull NYU Hosp Jt Dis 2008;66(2):150-4.

Patented Medicine Prices Review Board of Canada. Potential savings from biosimilars in Canada. 2018. Available: http://www.pmprb-cepmb.gc.ca/view.asp?ccid=1304 (accessed Oct. 11, 2018).

CADTH. Biosimilars—regulatory, health technology assessment, reimbursement trends and market outlook. Ottawa (ON):CADTH; 2018. Available: https://www.cadth.ca/sites/default/files/pdf/ES0317_biosimilars.pdf (accessed Oct. 11, 2018).

Government of British Columbia. Biosimilars initiative for patients. 2019. Available: https://www2.gov.bc.ca/gov/content/health/health-drug-coverage/pharmacare-for-bc-residents/what-we-cover/drug-coverage/biosimilars-initiative-patients (accessed Sept. 4, 2019).

Martell A Lampert A. British Columbia to be first Canadian province to switch patients to biosimilars. 2019, May 27. Available: https://www.reuters.com/article/us-canada-pharmaceuticals-biosimilars/british-columbia-to-be-first-canadian-province-to-switch-patients-to-biosimilars-idUSKCN1SX1VS (accessed Sept. 7, 2019).

Sullivan E Piercy J Waller J Black CM Kachroo S. Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn’s disease across Germany. PLoS One 2017;12(4):e0175826.

Beck M Michel B Rybarczyk-Vigouret MC , et al. Knowledge, behaviours and practices of community and hospital pharmacists towards biosimilar medicines: results of a French web-based survey. MAbs 2017;9(2):383-90.

Crespi-Lofton J Skelton JB. The growing role of biologics and biosimilars in the United States: perspectives from the APhA Biologics and Biosimilars Stakeholder Conference. J Am Pharm Assoc 2017;57(5):e15-e27.

Rezk MF Pieper B. To see or nosee: the debate on the nocebo effect and optimizing the use of biosimilars. Adv Ther 2018;35(6):749-53.

Rezk MF Pieper B. Treatment outcomes with biosimilars: be aware of the nocebo effect. Rheumatol Ther 2017;4(2):209-18.

Planes S Villier C Mallaret M. The nocebo effect of drugs. Pharmacol Res Perspect 2016;4(2):e00208.

Boone NW Liu L Romberg-Camps MJ , et al. The nocebo effect challenges the non-medical infliximab switch in practice. Eur J Clin Pharmacol 2018;74(5):655-61.

Jorgensen KK Olsen IC Goll GL , et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 2017;389(10086): 2304-16.

Odinet JS Day CE Cruz JL Heindel GA. The biosimilar nocebo effect? A systematic review of double-blinded versus open-label studies. J Manag Care Spec Pharm 2018;24(10):952-9.

Tweehuysen L Huiskes VJB van den Bemt BJF , et al. Open-label, nonmandatory transitioning from originator Etanercept to biosimilar SB4: six-month results from a controlled cohort study. Arthritis Rheumatol 2018;70(9):1408-18.

Tweehuysen L Huiskes V Bemt BVD , et al. FR10200 higher acceptance and persistence rates after biosimilar transitioning in patients with a rheumatic disease after employing an enhanced communication strategy. Ann Rheum Dis 2017;76(Suppl 2):557.